Índice de contenido

	Regulatory Challenges
		Drug regulatory authorities recommend action
	Essential Medicines
		Treating 3 million people living with HIV/AIDS by 2005
		AIDS medicines and diagnostics service
		Fixed-dose combination therapy
		HIV antiretrovirals and diagnostics funding
		World Bank ARV procurement manual
		Research on new HIV microbicides
	Safety and Efficacy Issues
		Safety of HIV therapies targeted by new advisory committee
		The risks and benefits of HRT
		Macrolides and warfarin interaction
		Statin risk factors: myopathy and rhabdomyolysis
		Serotonin syndrome
		Antidepressants: worsening depression and suicidal behaviour
		Use of SSRI antidepressants in children and adolescents
		Repaglinide and gemfibrozil interaction
	Vaccines and Biomedicines
		World's biological experts establish standards
		International Reference Materials
		Quality, safety and efficacy of biological medicines
	Herbal Medicines
		Regulation of traditional medicines in Africa
		Herbal medicines, patient safety and plant conservation
	Regulatory and Safety Action
		Nevirapine and hepatotoxicity
		Antidepressants in adults and children
		Recommended influenza vaccines: 2004-2005
		Olanzapine and cerebrovascular events
		Olanzapine: hyperglycaemia and diabetes
		Better labelling for ingredient sensitivities
	Consultation Document
		The International Pharmacopoeia - monographs for antiretrovirals
		Indinavir sulfate
		Nelfinavir mesilate
		Nevirapine anhydrous
	Proposed International Nonproprietary Names: List 90
	Recommended International Nonproprietary Names: List 51

WHO Drug Information Vol. 18, No. 1, 2004

World Health Organization

WHO Drug Information
is now available at:
http://www.who.int/druginformation